School of Medicine


Showing 1-4 of 4 Results

  • Youn H Kim, MD

    Youn H Kim, MD

    The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)

    Current Research and Scholarly InterestsClinical research in cutaneous lymphomas, especially, mycosis fungoides; studies of prognostic factors, long-term survival results, and effects of therapies. Collaborative research with Departments of Pathology and Oncology in basic mechanisms of cutaneous lymphomas. Clinical trials of new investigative therapies for various dermatologic conditions or clinical trials of known therapies for new indications.

  • Anandi Krishnan

    Anandi Krishnan

    Affiliate, Institute for Immunity, Transplantation, and Infection Operations
    Visiting Scholar, Institute for Immunity, Transplantation, and Infection Operations

    BioDr. Krishnan is a translational scientist with experiences in engineering, biosciences, molecular genetics and hematology. As a current NIH mentored career development awardee (NHGRI 1K08HG010061-01A1), and recent NIH-supported research re-entry (NCATS 3UL1TR001085-04S1), Anandi’s interests are in expanding our understanding of the multifaceted function of anucleate blood platelets and their parent megakaryocytes in human disease.

    Her current work, applying platelet transcriptome profiling and machine learning principles, aims to nominate novel clinically relevant strategies for personalized cancer and antiplatelet/antithrombotic therapy. Continued development of this research is likely to identify key mechanistic variables in platelet- and megakaryocyte-specific response to health and disease.

    Recent contributions in both computational and mechanistic components of platelet and blood research lay the groundwork for sustaining contributions to the field of hematology genomic medicine (e.g. Shen et al PMID 34755136, Seetharam et al PMID 36712071, Kelliher et al PMID 37961700, Thomas & Krishnan PMID 38175681, Abbonante et al PMID 38165147, Jutzi et al PMID 35763665, Campbell et al PMID 36194487). Anandi was also was one of the first non-MD PhD scientist to be awarded the NHGRI K08 Clinical Scientist Research Career Development Award, the HTRS Mid-Career Research Award, and the MPN Research Foundation Challenge Grant Award, reflecting her consistent efforts bridging basic and clinical disciplines.

    Select other recognitions include:
    Member, Editorial Board, Journal of Thrombosis and Haemostasis (2024-)
    Ad hoc Reviewer, NIH CSR Cancer and Hematological Disorders Study Section (2023, 24)
    Host Mentor, ISTH Training Fellowship, International Society for Thrombosis and Haemostasis (2023)
    Member, Minority Recruitment Initiatives Subcommittee, American Society of Hematology (2022-26)
    Team Science Leadership Program at Stanford Medicine (2022)
    Peer Mentor, Pathology Stanford Network for Advancement and Promotion (2021)
    Research Mentor, Meharry Medical College, Nashville, Meharry-Stanford initiative *mentee selected for oral presentation & won 2nd place at Meharry (2021)
    Thrombosis & Hemostasis Societies of North America Young Investigator Award (2020)
    Invited Member and Panelist, NSF RESET Conference (2020)
    Invited Member/Panelist, iRelaunch Return to Work Conference, Stanford Alumni Association (2018)
    Featured twice by NIH NCATS in the ‘Features & Briefs’ & ‘Diversity Awardee Profiles’ webpages (2017,18)

    Complete list of publications: https://pubmed.ncbi.nlm.nih.gov/?term=anandi+krishnan&sort_order=asc

  • David Kurtz

    David Kurtz

    Assistant Professor of Medicine (Oncology)
    On Partial Leave from 05/01/2024 To 04/30/2025

    Current Research and Scholarly InterestsImplementation of noninvasive detection of malignancies in the clinic remains difficult due to both technical and clinical challenges. These include necessary improvements in sensitivity and specificity of biomarkers, as well as demonstration of clinical utility of these assays. My research focuses on technical development and implementation of assays to detect and track cancers in order to facilitate personalized disease management.